Beck–Fahrner syndrome

From WikiMD's Medical Encyclopedia

Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics

Beck–Fahrner syndrome
Synonyms
Pronounce
Specialty Medical genetics
Symptoms Developmental delay, intellectual disability, distinctive facial features
Complications N/A
Onset
Duration
Types
Causes Genetic mutation in the TET3 gene
Risks
Diagnosis Genetic testing, clinical evaluation
Differential diagnosis
Prevention
Treatment Supportive care, individualized therapy
Medication
Prognosis Varies
Frequency Rare
Deaths


TET enzymes and 5hmC in epigenetic regulation of mammalian neurobiology
Beck–Fahrner syndrome or TET3 deficiency episignature

Beck-Fahrner Syndrome (BFS) is a rare genetic disorder characterized by a spectrum of developmental and physical anomalies. It is caused by mutations in the ZNF462 gene, which plays a crucial role in the regulation of gene expression during embryonic development. This syndrome was first described by Beck and Fahrner in the early 21st century, highlighting its recent discovery in the field of genetics.

Symptoms and Characteristics[edit]

Beck-Fahrner Syndrome presents a wide range of symptoms, which can vary significantly among affected individuals. Common characteristics include:

  • Developmental Delays: Individuals with BFS often experience delays in reaching developmental milestones, such as walking and talking.
  • Intellectual Disability: Mild to moderate intellectual disability is common among those diagnosed with BFS.
  • Facial Dysmorphisms: Distinctive facial features may include a broad forehead, widely spaced eyes (hypertelorism), a small jaw (micrognathia), and low-set ears.
  • Skeletal Anomalies: Skeletal issues, such as scoliosis or abnormalities in the fingers and toes, may be present.
  • Growth Abnormalities: Affected individuals might exhibit growth abnormalities, including both growth retardation and overgrowth.

Genetics[edit]

Beck-Fahrner Syndrome is caused by mutations in the ZNF462 gene, which is located on chromosome 9. The ZNF462 gene encodes a zinc finger protein that is involved in the regulation of other genes, playing a critical role in early development. BFS is inherited in an autosomal dominant manner, meaning that only one copy of the altered gene in each cell is sufficient to cause the disorder. However, many cases result from new mutations in the gene and occur in people with no history of the disorder in their family.

Diagnosis[edit]

Diagnosis of Beck-Fahrner Syndrome is based on clinical evaluation and the identification of characteristic symptoms. Genetic testing can confirm the diagnosis by detecting mutations in the ZNF462 gene. Prenatal testing may be available for families with a known history of BFS.

Management and Treatment[edit]

There is no cure for Beck-Fahrner Syndrome, and treatment is symptomatic and supportive. Management strategies may include:

  • Early Intervention Programs: To address developmental delays and intellectual disability.
  • Therapeutic Services: Physical, occupational, and speech therapies can help improve motor skills and communication abilities.
  • Medical Management: Treatment for skeletal anomalies, growth issues, and other medical concerns as needed.
  • Educational Support: Special education programs and resources to support learning and development.

Prognosis[edit]

The prognosis for individuals with Beck-Fahrner Syndrome varies depending on the severity of symptoms and the effectiveness of management strategies. With appropriate support, many affected individuals can lead fulfilling lives.

See Also[edit]

Stub icon
   This article is a medical stub. You can help WikiMD by expanding it!



Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.